NCT07338097Enrolling by invitation
Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema
Source: ClinicalTrials.gov · Last updated 13 Jan 2026
Brief summary (registry, in English)
Diabetic macular edema is a frequent complication of long-standing diabetes mellitus in which fluid leaks into the central part of the retina (macula), leading to reduced vision. This randomized controlled trial will be conducted at Combined Military Hospital, Multan, to compare two commonly used intravitreal anti vascular endothelial growth factor medicines, aflibercept and bevacizumab, in adults aged 30 to 60 years with type 1 or type 2 diabetes mellitus for at least 5 years, central macular thickness of at least 300 micrometers on optical coherence tomography, and reduced baseline visual acuity (20/50 or worse). Eligible participants will be allocated in a 1:1 ratio to receive either intravitreal aflibercept 2.0 mg or intravitreal bevacizumab 1.25 mg, administered monthly for two months, with follow-up assessments at 1 and 2 months. The primary hypothesis is that aflibercept produces a greater average improvement in visual acuity than bevacizumab in this patient group. The primary outcome is the mean change in visual acuity measured as Early Treatment Diabetic Retinopathy Study letter score from baseline to 2 months. The secondary outcome is the mean change in central retinal thickness on optical coherence tomography.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 116 (estimated)
- First submitted
- 3 Jan 2026
- Start date
- 7 Sept 2025
- Primary completion date
- 7 Feb 2026
- Lead sponsor
- CMH Multan Institute of Medical Sciences
- Diseases
- Diabetic eye disease
- NCT number
- NCT07338097
What you commit to
- Study type: Interventional
- Planned participants: 116
- From 7 Sept 2025 to the primary completion date, 7 Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of prior treatment for DME: anti-VEGF, steroids, or laser.
Other illness
- Active ocular infection or inflammation
- History of cardiac disease or stroke
- Known allergy to Aflibercept or Bevacizumab
Other
- Women who are pregnant or breastfeeding
- Patient refusals to participate in the study
Who the study is looking for
- Patients with type 1 or type 2 diabetes mellitus for ≥5 years
- Baseline visual acuity of 20/50 or worse
- Central macular thickness of ≥300 µm on OCT
- Age 30 to 60 years
- Either gender
- Provided voluntary consent for participation
Age in the registry: 30 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CMH Institute of Medical Sciences Coordinator of this site? Confirm its status | Multan | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.